MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 22, 2006; DOI: 10.1124/mol.106.025494


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025494v1
70/3/887    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kikuchi, R.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kikuchi, R.
Right arrow Articles by Sugiyama, Y.


Received for publication April 10, 2006.
Revised June 8, 2006.
Accepted for publication June 20, 2006.

Regulation of the Expression of Human Organic Anion Transporter 3 by Hepatocyte Nuclear Factor 1{alpha}/{beta} and DNA Methylation

Ryota Kikuchi 1, Hiroyuki Kusuhara 1, Naka Hattori 2, Kunio Shiota 2, Insook Kim 3, Frank J Gonzalez 3, Yuichi Sugiyama 1*

1 Dept. of Molecular Pharmacokinetics, Grad. Sch. of Pharm. Sci., Univ. Tokyo 2 Lab. of Cell. Biochem., Dept. of Animal Resource Sci./Veterinary Medical Sci., Univ. Tokyo 3 Lab. of Metabolism, National Cancer Institute, NIH

* Address correspondence to: E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp

Abstract

Human Organic Anion Transporter 3 (hOAT3/SLC22A8) is predominantly expressed in the proximal tubules of the kidney, and plays a major role in the urinary excretion of a variety of organic anions. The promoter region of hOAT3 was characterized to elucidate the mechanism underlying the tissue specific expression of hOAT3. The minimal promoter of hOAT3 was identified to be located approximately 300 bp upstream of the transcriptional start site, where there are canonical TATA and HNF1 binding motifs, which are conserved in the rodent Oat3 genes. Transactivation assays revealed that HNF1{alpha} and HNF1{beta} markedly increased hOAT3 promoter activity, where the transactivation potency of HNF1{beta} was lower than that of HNF1{alpha}. Mutations in the HNF1 binding motif prevented the transactivation. Electrophoretic mobility shift assays demonstrated binding of the HNF1{alpha}/HNF1{alpha} homodimer or HNF1{alpha}/HNF1{beta} heterodimer to the hOAT3 promoter. It was also demonstrated that the promoter activity of hOAT3 is repressed by DNA methylation. Moreover, the expression of hOAT3 was activated de novo by forced expression of HNF1{alpha} alone or both HNF1{alpha} and HNF1{beta} together with the concomitant DNA demethylation in HEK293 cells that lack expression of endogenous HNF1{alpha} and HNF1{beta}, whereas forced expression of HNF1{beta} alone could not activate the expression of hOAT3. This suggests a synergistic action of the HNF1{alpha}/HNF1{alpha} homodimer or HNF1{alpha}/HNF1{beta} heterodimer and DNA demethylation for the constitutive expression of hOAT3. These results indicate that the tissue specific expression of hOAT3 might be regulated by the concerted effect of genetic (HNF1{alpha} and HNF1{beta}) and epigenetic (DNA methylation) factors.


Key words: Promoter analysis, Organic anion, Regulation - transcriptional


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
S.-Y. Ahn and S. K. Nigam
Toward a Systems Level Understanding of Organic Anion and Other Multispecific Drug Transporters: A Remote Sensing and Signaling Hypothesis
Mol. Pharmacol., September 1, 2009; 76(3): 481 - 490.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. Adalat, A. S. Woolf, K. A. Johnstone, A. Wirsing, L. W. Harries, D. A. Long, R. C. Hennekam, S. E. Ledermann, L. Rees, W. van't Hoff, et al.
HNF1B Mutations Associate with Hypomagnesemia and Renal Magnesium Wasting
J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1123 - 1131.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. W. Yee, J. E. Shima, S. Hesselson, L. Nguyen, S. De Val, R. J. LaFond, M. Kawamoto, S. J. Johns, D. Stryke, P.-Y. Kwok, et al.
Identification and Characterization of Proximal Promoter Polymorphisms in the Human Concentrative Nucleoside Transporter 2 (SLC28A2)
J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 699 - 707.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Imai, R. Kikuchi, H. Kusuhara, S. Yagi, K. Shiota, and Y. Sugiyama
Analysis of DNA Methylation and Histone Modification Profiles of Liver-Specific Transporters
Mol. Pharmacol., March 1, 2009; 75(3): 568 - 576.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Saji, R. Kikuchi, H. Kusuhara, I. Kim, F. J. Gonzalez, and Y. Sugiyama
Transcriptional Regulation of Human and Mouse Organic Anion Transporter 1 by Hepatocyte Nuclear Factor 1 {alpha}/{beta}
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 784 - 790.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Kikuchi, H. Kusuhara, N. Hattori, I. Kim, K. Shiota, F. J. Gonzalez, and Y. Sugiyama
Regulation of Tissue-Specific Expression of the Human and Mouse Urate Transporter 1 Gene by Hepatocyte Nuclear Factor 1 {alpha}/beta and DNA Methylation
Mol. Pharmacol., December 1, 2007; 72(6): 1619 - 1625.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Ogasawara, T. Terada, J.-i. Asaka, T. Katsura, and K.-i. Inui
Hepatocyte nuclear factor-4{alpha} regulates the human organic anion transporter 1 gene in the kidney
Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1819 - F1826.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J.-i. Asaka, T. Terada, K. Ogasawara, T. Katsura, and K.-i. Inui
Characterization of the Basal Promoter Element of Human Organic Cation Transporter 2 Gene
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 684 - 689.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics